PARP Inhibitors in Metastatic Prostate Cancer: Biomarker Testing, Treatment Strategies, and Toxicity Management

In this podcast episode, Neeraj Agarwal, MD, FASCO, and Emmanuel S. Antonarakis, MD, discuss the evolving role of PARP inhibitors in metastatic prostate cancer, emphasizing early molecular testing to identify appropriate patients for PARP-directed therapy and proactive adverse event management to support treatment continuation, including:

• HRR alterations and the mechanism of action of PARP inhibitors
• Germline and somatic genomic testing and practical considerations for tissue and ctDNA testing
• PARP inhibitor monotherapy and combination strategies, including data from AMPLITUDE and TALAPRO-3
• Treatment selection across metastatic prostate cancer settings based on HRR alterations
• PARP inhibitor toxicity management, with emphasis on anemia, gastrointestinal effects, monitoring, and dose modification

Presenters:

Neeraj Agarwal, MD, FASCO
Medical Oncologist, Dana-Farber Cancer Institute
Co-Director, Prostate Cancer Program, Harvard Cancer Consortium
The Lank Center for Genitourinary Oncology
Boston, Massachusetts

Emmanuel S. Antonarakis, MD
Clark Endowed Professor of Medicine
Director of GU Oncology, Associate Director of Translation
Division of Hematology, Oncology and Transplantation
University of Minnesota, Masonic Cancer Center
Minneapolis, Minnesota

Link to full program: 
https://bit.ly/4dtT35U

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.